52
|
Klint JK, Chin YKY, Mobli M. Rational Engineering Defines a Molecular Switch That Is Essential for Activity of Spider-Venom Peptides against the Analgesics Target NaV1.7. Mol Pharmacol 2015; 88:1002-10. [PMID: 26429937 DOI: 10.1124/mol.115.100784] [Citation(s) in RCA: 28] [Impact Index Per Article: 3.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/13/2015] [Accepted: 09/28/2015] [Indexed: 12/24/2022] Open
Abstract
Many spider-venom peptides are known to modulate the activity of the voltage-gated sodium (NaV) subtype 1.7 (NaV1.7) channel, which has emerged as a promising analgesic target. In particular, a class of spider-venom peptides (NaSpTx1) has been found to potently inhibit NaV1.7 (nanomolar IC50), and has been shown to produce analgesic effects in animals. However, one member of this family [µ-TRTX-Hhn2b (Hhn2b)] does not inhibit mammalian NaV channels expressed in dorsal root ganglia at concentrations up to 100 µM. This peptide is classified as a NaSpTx1 member by virtue of its cysteine spacing and sequence conservation over functionally important residues. Here, we have performed detailed structural and functional analyses of Hhn2b, leading us to identify two nonpharmacophore residues that contribute to human NaV1.7 (hNaV1.7) inhibition by nonoverlapping mechanisms. These findings allowed us to produce a double mutant of Hhn2b that shows nanomolar inhibition of hNaV1.7. Traditional structure/function analysis did not provide sufficient resolution to identify the mechanism underlying the observed gain of function. However, by solving the high-resolution structure of both the wild-type and mutant peptides using advanced multidimensional NMR experiments, we were able to uncover a previously unknown network of interactions that stabilize the pharmacophore region of this class of venom peptides. We further monitored the lipid binding properties of the peptides and identified that one of the key amino acid substitutions also selectively modulates the binding of the peptide to anionic lipids. These results will further aid the development of peptide-based analgesics for the treatment of chronic pain.
Collapse
Affiliation(s)
- Julie K Klint
- Institute for Molecular Bioscience, (J.K.K., Y.K.-Y.C.), and Centre for Advanced Imaging (M.M.), University of Queensland, St Lucia, Australia
| | - Yanni K-Y Chin
- Institute for Molecular Bioscience, (J.K.K., Y.K.-Y.C.), and Centre for Advanced Imaging (M.M.), University of Queensland, St Lucia, Australia
| | - Mehdi Mobli
- Institute for Molecular Bioscience, (J.K.K., Y.K.-Y.C.), and Centre for Advanced Imaging (M.M.), University of Queensland, St Lucia, Australia
| |
Collapse
|
53
|
Cai T, Luo J, Meng E, Ding J, Liang S, Wang S, Liu Z. Mapping the interaction site for the tarantula toxin hainantoxin-IV (β-TRTX-Hn2a) in the voltage sensor module of domain II of voltage-gated sodium channels. Peptides 2015; 68:148-56. [PMID: 25218973 DOI: 10.1016/j.peptides.2014.09.005] [Citation(s) in RCA: 30] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 08/01/2014] [Revised: 09/01/2014] [Accepted: 09/02/2014] [Indexed: 01/22/2023]
Abstract
Peptide toxins often have pharmacological applications and are powerful tools for investigating the structure-function relationships of voltage-gated sodium channels (VGSCs). Although a group of potential VGSC inhibitors have been reported from tarantula venoms, little is known about the mechanism of their interaction with VGSCs. In this study, we showed that hainantoxin-IV (β-TRTX-Hn2a, HNTX-IV in brief), a 35-residue peptide from Ornithoctonus hainana venom, preferentially inhibited rNav1.2, rNav1.3 and hNav1.7 compared with rNav1.4 and hNav1.5. hNav1.7 was the most sensitive to HNTX-IV (IC50∼21nM). In contrast to many other tarantula toxins that affect VGSCs, HNTX-IV at subsaturating concentrations did not alter activation and inactivation kinetics in the physiological range of voltages, while very large depolarization above +70mV could partially activate toxin-bound hNav1.7 channel, indicating that HNTX-IV acts as a gating modifier rather than a pore blocker. Site-directed mutagenesis indicated that the toxin bound to site 4, which was located on the extracellular S3-S4 linker of hNav1.7 domain II. Mutants E753Q, D816N and E818Q of hNav1.7 decreased toxin affinity for hNav1.7 by 2.0-, 3.3- and 130-fold, respectively. In silico docking indicated that a three-toed claw substructure formed by residues with close contacts in the interface between HNTX-IV and hNav1.7 domain II stabilized the toxin-channel complex, impeding movement of the domain II voltage sensor and inhibiting hNav1.7 activation. Our data provide structural details for structure-based drug design and a useful template for the design of highly selective inhibitors of a specific subtype of VGSCs.
Collapse
Affiliation(s)
- Tianfu Cai
- College of Life Sciences, Hunan Normal University, Changsha, 410081 Hunan, China
| | - Ji Luo
- College of Life Sciences, Hunan Normal University, Changsha, 410081 Hunan, China
| | - Er Meng
- Research Center of Biological Information, College of Science, National University of Defense Technology, Changsha, 410073 Hunan, China
| | - Jiuping Ding
- Key Laboratory of Molecular Biophysics, Huazhong University of Science and Technology, Ministry of Education, College of Life Science and Technology, Wuhan, Hubei 430074, China
| | - Songping Liang
- College of Life Sciences, Hunan Normal University, Changsha, 410081 Hunan, China
| | - Sheng Wang
- Key Laboratory of Molecular Biophysics, Huazhong University of Science and Technology, Ministry of Education, College of Life Science and Technology, Wuhan, Hubei 430074, China.
| | - Zhonghua Liu
- College of Life Sciences, Hunan Normal University, Changsha, 410081 Hunan, China.
| |
Collapse
|
54
|
Cardoso FC, Dekan Z, Rosengren KJ, Erickson A, Vetter I, Deuis JR, Herzig V, Alewood PF, King GF, Lewis RJ. Identification and Characterization of ProTx-III [μ-TRTX-Tp1a], a New Voltage-Gated Sodium Channel Inhibitor from Venom of the Tarantula Thrixopelma pruriens. Mol Pharmacol 2015; 88:291-303. [PMID: 25979003 DOI: 10.1124/mol.115.098178] [Citation(s) in RCA: 60] [Impact Index Per Article: 6.7] [Reference Citation Analysis] [Abstract] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/02/2015] [Accepted: 05/15/2015] [Indexed: 01/26/2023] Open
Abstract
Spider venoms are a rich source of ion channel modulators with therapeutic potential. Given the analgesic potential of subtype-selective inhibitors of voltage-gated sodium (NaV) channels, we screened spider venoms for inhibitors of human NaV1.7 (hNaV1.7) using a high-throughput fluorescent assay. Here, we describe the discovery of a novel NaV1.7 inhibitor, μ-TRTX-Tp1a (Tp1a), isolated from the venom of the Peruvian green-velvet tarantula Thrixopelma pruriens. Recombinant and synthetic forms of this 33-residue peptide preferentially inhibited hNaV1.7 > hNaV1.6 > hNaV1.2 > hNaV1.1 > hNaV1.3 channels in fluorescent assays. NaV1.7 inhibition was diminished (IC50 11.5 nM) and the association rate decreased for the C-terminal acid form of Tp1a compared with the native amidated form (IC50 2.1 nM), suggesting that the peptide C terminus contributes to its interaction with hNaV1.7. Tp1a had no effect on human voltage-gated calcium channels or nicotinic acetylcholine receptors at 5 μM. Unlike most spider toxins that modulate NaV channels, Tp1a inhibited hNaV1.7 without significantly altering the voltage dependence of activation or inactivation. Tp1a proved to be analgesic by reversing spontaneous pain induced in mice by intraplantar injection in OD1, a scorpion toxin that potentiates hNaV1.7. The structure of Tp1a as determined using NMR spectroscopy revealed a classic inhibitor cystine knot (ICK) motif. The molecular surface of Tp1a presents a hydrophobic patch surrounded by positively charged residues, with subtle differences from other ICK spider toxins that might contribute to its different pharmacological profile. Tp1a may help guide the development of more selective and potent hNaV1.7 inhibitors for treatment of chronic pain.
Collapse
Affiliation(s)
- Fernanda C Cardoso
- Institute for Molecular Bioscience (F.C.C., Z.D., I.V., J.R.D., V.H., P.F.A., G.F.K., R.J.L.), School of Biomedical Sciences (K.J.R.), and School of Chemistry and Molecular Biosciences (A.E.), The University of Queensland, Brisbane, Queensland, Australia
| | - Zoltan Dekan
- Institute for Molecular Bioscience (F.C.C., Z.D., I.V., J.R.D., V.H., P.F.A., G.F.K., R.J.L.), School of Biomedical Sciences (K.J.R.), and School of Chemistry and Molecular Biosciences (A.E.), The University of Queensland, Brisbane, Queensland, Australia
| | - K Johan Rosengren
- Institute for Molecular Bioscience (F.C.C., Z.D., I.V., J.R.D., V.H., P.F.A., G.F.K., R.J.L.), School of Biomedical Sciences (K.J.R.), and School of Chemistry and Molecular Biosciences (A.E.), The University of Queensland, Brisbane, Queensland, Australia
| | - Andelain Erickson
- Institute for Molecular Bioscience (F.C.C., Z.D., I.V., J.R.D., V.H., P.F.A., G.F.K., R.J.L.), School of Biomedical Sciences (K.J.R.), and School of Chemistry and Molecular Biosciences (A.E.), The University of Queensland, Brisbane, Queensland, Australia
| | - Irina Vetter
- Institute for Molecular Bioscience (F.C.C., Z.D., I.V., J.R.D., V.H., P.F.A., G.F.K., R.J.L.), School of Biomedical Sciences (K.J.R.), and School of Chemistry and Molecular Biosciences (A.E.), The University of Queensland, Brisbane, Queensland, Australia
| | - Jennifer R Deuis
- Institute for Molecular Bioscience (F.C.C., Z.D., I.V., J.R.D., V.H., P.F.A., G.F.K., R.J.L.), School of Biomedical Sciences (K.J.R.), and School of Chemistry and Molecular Biosciences (A.E.), The University of Queensland, Brisbane, Queensland, Australia
| | - Volker Herzig
- Institute for Molecular Bioscience (F.C.C., Z.D., I.V., J.R.D., V.H., P.F.A., G.F.K., R.J.L.), School of Biomedical Sciences (K.J.R.), and School of Chemistry and Molecular Biosciences (A.E.), The University of Queensland, Brisbane, Queensland, Australia
| | - Paul F Alewood
- Institute for Molecular Bioscience (F.C.C., Z.D., I.V., J.R.D., V.H., P.F.A., G.F.K., R.J.L.), School of Biomedical Sciences (K.J.R.), and School of Chemistry and Molecular Biosciences (A.E.), The University of Queensland, Brisbane, Queensland, Australia
| | - Glenn F King
- Institute for Molecular Bioscience (F.C.C., Z.D., I.V., J.R.D., V.H., P.F.A., G.F.K., R.J.L.), School of Biomedical Sciences (K.J.R.), and School of Chemistry and Molecular Biosciences (A.E.), The University of Queensland, Brisbane, Queensland, Australia
| | - Richard J Lewis
- Institute for Molecular Bioscience (F.C.C., Z.D., I.V., J.R.D., V.H., P.F.A., G.F.K., R.J.L.), School of Biomedical Sciences (K.J.R.), and School of Chemistry and Molecular Biosciences (A.E.), The University of Queensland, Brisbane, Queensland, Australia
| |
Collapse
|
55
|
Klint JK, Smith JJ, Vetter I, Rupasinghe DB, Er SY, Senff S, Herzig V, Mobli M, Lewis RJ, Bosmans F, King GF. Seven novel modulators of the analgesic target NaV 1.7 uncovered using a high-throughput venom-based discovery approach. Br J Pharmacol 2015; 172:2445-58. [PMID: 25754331 DOI: 10.1111/bph.13081] [Citation(s) in RCA: 69] [Impact Index Per Article: 7.7] [Reference Citation Analysis] [Abstract] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/03/2014] [Revised: 11/08/2014] [Accepted: 12/08/2014] [Indexed: 12/19/2022] Open
Abstract
BACKGROUND AND PURPOSE Chronic pain is a serious worldwide health issue, with current analgesics having limited efficacy and dose-limiting side effects. Humans with loss-of-function mutations in the voltage-gated sodium channel NaV 1.7 (hNaV 1.7) are indifferent to pain, making hNaV 1.7 a promising target for analgesic development. Since spider venoms are replete with NaV channel modulators, we examined their potential as a source of hNaV 1.7 inhibitors. EXPERIMENTAL APPROACH We developed a high-throughput fluorescent-based assay to screen spider venoms against hNaV 1.7 and isolate 'hit' peptides. To examine the binding site of these peptides, we constructed a panel of chimeric channels in which the S3b-S4 paddle motif from each voltage sensor domain of hNaV 1.7 was transplanted into the homotetrameric KV 2.1 channel. KEY RESULTS We screened 205 spider venoms and found that 40% contain at least one inhibitor of hNaV 1.7. By deconvoluting 'hit' venoms, we discovered seven novel members of the NaSpTx family 1. One of these peptides, Hd1a (peptide μ-TRTX-Hd1a from venom of the spider Haplopelma doriae), inhibited hNaV 1.7 with a high level of selectivity over all other subtypes, except hNaV 1.1. We showed that Hd1a is a gating modifier that inhibits hNaV 1.7 by interacting with the S3b-S4 paddle motif in channel domain II. The structure of Hd1a, determined using heteronuclear NMR, contains an inhibitor cystine knot motif that is likely to confer high levels of chemical, thermal and biological stability. CONCLUSION AND IMPLICATIONS Our data indicate that spider venoms are a rich natural source of hNaV 1.7 inhibitors that might be useful leads for the development of novel analgesics.
Collapse
Affiliation(s)
- Julie K Klint
- Centre for Pain Research, Institute for Molecular Bioscience, St. Lucia, Qld, Australia
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
57
|
Wilkinson TCI, Gardener MJ, Williams WA. Discovery of Functional Antibodies Targeting Ion Channels. ACTA ACUST UNITED AC 2014; 20:454-67. [DOI: 10.1177/1087057114560698] [Citation(s) in RCA: 30] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/19/2022]
Abstract
Ion channels play critical roles in physiology and disease by modulation of cellular functions such as electrical excitability, secretion, cell migration, and gene transcription. Ion channels represent an important target class for drug discovery that has been largely addressed, to date, using small-molecule approaches. A significant opportunity exists to target these channels with antibodies and alternative formats of biologics. Antibodies display high specificity and affinity for their target antigen, and they have the potential to target ion channels very selectively. Nevertheless, isolating antibodies to this target class is challenging due to the difficulties in expression and purification of ion channels in a format suitable for antibody drug discovery in addition to the complexity of screening for function. In this article, we will review the current state of ion channel biologics discovery and the progress that has been made. We will also highlight the challenges in isolating functional antibodies to these targets and how these challenges may be addressed. Finally, we also illustrate successful approaches to isolating functional monoclonal antibodies targeting ion channels by way of a number of case studies drawn from recent publications.
Collapse
Affiliation(s)
| | | | - Wendy A. Williams
- Antibody Discovery and Protein Engineering, MedImmune, Cambridge, UK
| |
Collapse
|
58
|
Bagal SK, Chapman ML, Marron BE, Prime R, Storer RI, Swain NA. Recent progress in sodium channel modulators for pain. Bioorg Med Chem Lett 2014; 24:3690-9. [PMID: 25060923 DOI: 10.1016/j.bmcl.2014.06.038] [Citation(s) in RCA: 128] [Impact Index Per Article: 12.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/29/2014] [Revised: 06/11/2014] [Accepted: 06/12/2014] [Indexed: 01/15/2023]
Abstract
Voltage-gated sodium channels (Navs) are an important family of transmembrane ion channel proteins and Nav drug discovery is an exciting field. Pharmaceutical investment in Navs for pain therapeutics has expanded exponentially due to genetic data such as SCN10A mutations and an improved ability to establish an effective screen sequence for example IonWorks Barracuda®, Synchropatch® and Qube®. Moreover, emerging clinical data (AZD-3161, XEN402, CNV1014802, PF-05089771, PF-04531083) combined with recent breakthroughs in Nav structural biology pave the way for a future of fruitful prospective Nav drug discovery.
Collapse
Affiliation(s)
- Sharan K Bagal
- Worldwide Medicinal Chemistry, Pfizer Neusentis, The Portway Building, Granta Park, Great Abington, Cambridge CB21 6GS, UK.
| | - Mark L Chapman
- Electrophysiology, Pfizer Neusentis, 4222 Emperor Blvd., Durham, NC, USA
| | - Brian E Marron
- Chemistry, Pfizer Neusentis, 4222 Emperor Blvd., Durham, NC, USA
| | - Rebecca Prime
- Electrophysiology, Pfizer Neusentis, The Portway Building, Granta Park, Great Abington, Cambridge CB21 6GS, UK
| | - R Ian Storer
- Worldwide Medicinal Chemistry, Pfizer Neusentis, The Portway Building, Granta Park, Great Abington, Cambridge CB21 6GS, UK
| | - Nigel A Swain
- Worldwide Medicinal Chemistry, Pfizer Neusentis, The Portway Building, Granta Park, Great Abington, Cambridge CB21 6GS, UK
| |
Collapse
|